Lyso­gene rais­es $25M in Paris IPO; Chan Zucker­berg Bio­hub starts hand­ing out $50M

• The gene ther­a­py com­pa­ny Lyso­gene has raised $25 mil­lion from an IPO on Eu­ronext Paris de­signed to fund its R&D work. “This IPO will en­able us to pur­sue the de­vel­op­ment of two drugs to treat two polys­dis­abling, dev­as­tat­ing and dead­ly dis­eases of the cen­tral ner­vous sys­tem, which start in in­fan­cy and lead to the pa­tients pre­ma­ture death,” said CEO Karen Aiach. “By fo­cus­ing di­rect­ly on the cause, our treat­ments aim to cure these dis­eases the med­ical needs of which are large­ly un­sat­is­fied and cur­rent­ly un­cov­ered.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER